This bioscience company has had promising financials, yet one of its top executives exited his entire direct equity ownership ...

Twist Bioscience Corporation Q1 2026 revenue rose 17% and guidance increased. Click for this updated look at TWST stock ...

Lexaria Bioscience (NASDAQ:LEXX) was trading lower after the drug delivery platform announced a sale of 2,666,667 shares, par value $0.001 per share, at $1.50 per share in a registered direct offering ...

D. Boral Capital upgraded Artelo Biosciences, Inc. (NASDAQ:ARTL) on Tuesday. The analyst upgraded from Hold to Buy and introduced a price forecast of $20. Analyst Jason Kolbert wrote, “We continue to ...

The biotech company posted revenue of $103.7 million for the quarter ended December 31, 2025, surpassing the analyst consensus of $100.72 million and representing a 17% increase from $88.7 million in ...

BD (NYSE: BDX) today set the record date for the planned spin-off of its Biosciences & Diagnostics business to Waters ...

It is being acquired for quite a meaty premium. The buyer is a top name in the global pharmaceuticals space. The purchasing party is global pharmaceutical company Novartis, which on Sunday divulged ...

Days after starting a new investigational program, it announced four appointments to its scientific advisory board. All of these professionals are experts in the affliction being targeted. Less than ...

LEXARIA BIOSCIENCE ($LEXX) is expected to release its quarterly earnings data on Thursday, July 10th before market open, per Finnhub. Analysts are expecting revenue ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $45.86, with a ...